Orchestra BioMed Holdings, Inc. (OBIO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Orchestra BioMed is a biomedical innovation company focused on developing high-impact technologies through partnerships. Its lead product candidates are AVIM therapy (BackBeat CNT) for hypertension, developed in collaboration with Medtronic, and Virtue SAB for atherosclerotic artery disease, developed in collaboration with Terumo. The company also generates minor product revenue from FreeHold Surgical's intracorporeal organ retractors.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $1,398 |
| Net Loss | $(29,443) |
| Net Loss Per Share (Basic & Diluted) | $(0.82) |
| Research & Development Expenses | $20,238 |
| Selling, General & Administrative Expenses | $12,364 |
| Cash and Cash Equivalents | $23,713 |
| Marketable Securities | $41,468 |
| Total Liquidity (Cash + Securities) | $65,181 |
| Accumulated Deficit | $(278,297) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 33% to $1.4 million from $2.1 million in the prior year period. Partnership revenue dropped 36% due to changes in cost estimates for the Terumo Agreement, and product revenue fell 18% due to lower sales volume of FreeHold retractors.
- Increased Expenses: R&D expenses rose 21% to $20.2 million, driven by increased headcount, stock-based compensation, and non-clinical development costs for the BackBeat and Virtue SAB programs. SG&A expenses increased 27% to $12.4 million, primarily due to higher stock-based compensation and public company compliance costs.
- Wider Net Loss: Net loss increased 28% to $29.4 million from $23.0 million year-over-year.
- Debt Status: The company has no outstanding debt as of June 30, 2024, having repaid its 2022 Loan and Security Agreement in October 2023.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management estimates current cash, cash equivalents, and marketable securities are sufficient to fund operations into the second half of 2026.
- Recent Financing: On July 11, 2024 (subsequent to the reporting period), the company sold 2 million shares under its ATM agreement, raising approximately $15.5 million in gross proceeds.
- Terumo Agreement Restructuring: The company has delayed the initiation of the Virtue ISR-US pivotal study pending a restructuring of the Terumo Agreement to secure additional capital. The company missed target dates for three $5 million milestone payments and is unlikely to earn the remaining $20 million in time-based milestones without agreement modifications.
- Medtronic Collaboration: The company is advancing the BACKBEAT pivotal study for AVIM therapy, with enrollment commencing in January 2024. No revenue has been recognized under the Medtronic Agreement to date.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital if the Terumo restructuring is not favorable, and the potential dilution from future equity issuances.
Investor Verification Checklist
- Terumo Restructuring Status: Verify the progress of negotiations with Terumo regarding milestone payments and additional funding commitments, as this impacts the Virtue SAB timeline.
- ATM Utilization: Monitor the pace of share sales under the $100 million ATM facility and the impact on share price and dilution.
- Burn Rate vs. Runway: Confirm that the projected runway to late 2026 holds given the increased R&D spend and the delay in Virtue SAB revenue recognition.
- BackBeat Pivotal Study: Track enrollment rates and interim data for the BACKBEAT study, which is the primary driver for future Medtronic-related revenue.
- Stock-Based Compensation: Review the $20.8 million in unrecognized stock-based compensation expense, which will impact future earnings.